Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. It offers psychotropic drugs for the treatment of neurological disorders such as narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain, psychiatric conditions, and epilepsy. The company was founded by Franck Joseph Louis Mouthon and Mathieu Bernard Mari Charveriat on March 19, 2013 and is headquartered in Lyon, France.